Research and analysis

Provisional childhood vaccination coverage: April 2026

Published 25 June 2026

Applies to England

1. Introduction

This report presents provisional childhood vaccine coverage statistics for MMRV, MenB, the hexavalent (‘6-in-1’) and rotavirus vaccines, and for the dTaP/IPV booster, for April 2026 in England.

Cover of Vaccination Evaluated Rapidly (COVER) reports remain the official source for childhood vaccination coverage data. The aim of this supplementary report is to provide more timely, provisional estimates to support staff delivering the childhood immunisation programme.

Coverage estimates in this report will differ from the official figures published in COVER, as the reports use different data sources and methodologies. This report is based on GP data meaning unregistered individuals are not included so figures do not capture the entire eligible population. For more details on both data sources and appropriate use cases please see the Methods section.

In this report, coverage is measured in those turning each age within the survey month and estimates include vaccinations administered up to the end of the survey month. This methodology means that for each age band, coverage is measured in a different cohort of children each month.

Coverage by local authority is likely to be variable, as the number of eligible individuals in each cohort is often small. This should be taken into account when interpreting these coverage estimates.

Historic data has been excluded for: MenB for April 2020, March 2022, May 2022, October 2022 and between September 2025 and December 2025; for the 6‑in‑1 vaccine between May 2022 and March 2023 and in October 2025; and for rotavirus in September 2023. These periods are indicated by grey bars in the graphs in this report.

In addition, all historic data has been excluded for the dTaP/IPV booster. Data from these periods were excluded after failing validation checks.

Sufficient data is not yet available to assess whether the introduction of the 18 month appointment has improved coverage of MMRV dose 1 and to assess coverage of MMRV dose 2 but this will be included in future publications.

2. Main points

The main findings are that:

• MMRV dose 1 coverage in those aged 15 months (1 year and 3 months) remained similar to coverage of MMR measured in children of the same age before the switch to the MMRV vaccine, on 1 January 2026, suggesting a successful transition to MMRV
• MenB dose 2 coverage in those aged 6 months has increased, suggesting the change in schedule, with an earlier offer of dose 2, has had a positive impact on coverage
• 6-in-1 dose 2 coverage was 90.4% in those aged 6 months, 1.0 percentage points lower than in April 2025
• MenB dose 3 coverage was 83.8% in those aged 18 months (1 year 6 months), 0.3 percentage points lower than in April 2025
• rotavirus dose 2 coverage was 86.7% in those aged 6 months, 2.0 percentage points lower than in April 2025
• dTaP/IPV booster coverage was 83.3% in those aged 60 months (5 years)

Results for individual vaccines

3. The MMRV vaccine

3.1. Summary of MMRV vaccine coverage

The MMRV vaccine provides protection against measles, mumps, rubella and varicella. From January 2026, the MMR vaccine was replaced with MMRV, offering children additional protection against varicella, which causes chickenpox. Children become eligible for the MMRV dose 1 at 12 months.

Although most individuals in the 15 month cohort should have received MMRV, a small number are recorded as having received MMR. These children may have received MMR in another country or had their vaccine type coded incorrectly.

The impact of the transition to MMRV on coverage is evaluated for dose 1 in those aged 15 months (1 year and 3 months). Those aged 15 months were eligible for the first dose of MMRV at 12 months, meaning they had been eligible for 3 months when measured.

Sufficient data is not yet available to assess whether the introduction of the 18 month appointment has improved coverage of MMRV dose 1, nor to assess coverage of MMRV dose 2, but these will be addressed in future publications.

Coverage of MMRV dose 1: cohort turning 15 months

The measurement of coverage for MMRV dose 1 at 15 months provides an indicator of current coverage, as well as timeliness of vaccination (defined as those vaccinated within 3 months of becoming eligible) and allows us to assess the transition to the new MMRV programme.

The findings for MMRV dose 1 in those aged 15 months are that:

• coverage of MMR-containing (MMR or MMRV) dose 1 was 78.8% (35,835 out of 45,488), 98.7% of which were recorded as MMRV doses
• coverage was comparable to April 2025, prior to the introduction of MMRV (0.1 percentage points lower)
• coverage by commissioning region differed by 11.0 percentage points, from 72.0% in London to 83.0% in the South West
• coverage by local authority differed by 38.7 percentage points, from 55.2% in Hackney and City of London to 93.9% in Dorset
• coverage by IMD 2025 decile differed by 15.2 percentage points, from 71.5% in the most deprived decile to 86.7% in the least deprived decile

Table 1. MMRV dose 1 coverage (%) in those aged 15 months (1 year and 3 months) by commissioning region in April 2026

Commissioning region	MMRV dose 1 coverage (%)
North East and Yorkshire	81.0
North West	76.8
Midlands	78.6
East of England	81.9
South East	82.0
London	72.0
South West	83.0
Total	78.8

Figure 1a. MMR and MMRV dose 1 coverage (%) in those aged 15 months (1 year and 3 months) from April 2023 to April 2026

Figure 1b. MMR and MMRV dose 1 coverage (%) in those aged 15 months (1 year and 3 months) from April 2023 to April 2026 by historic commissioning region

Figure 1c. MMRV dose 1 coverage for those aged 15 months (1 year 3 months) for April 2026 by local authority

3.2. The MenB vaccine

Summary of MenB coverage

The MenB vaccine provides protection against meningococcal group B (MenB) bacteria which causes meningitis and sepsis. Children are eligible for a primary course of dose 1 at 2 months (8 weeks) and dose 2 at 3 months (12 weeks) with an additional booster dose at 12 months. From July 2025 onwards, the second dose of MenB was moved forward from 4 months (16 weeks) to 3 months (12 weeks).

The main findings for the MenB vaccine are that:

• dose 1 coverage was 93.3% at 6 months, 94.0% at 12 months, 94.6% at 18 months (1 year 6 months)
• dose 2 coverage was 89.8% at 6 months, 91.6% at 12 months, 91.8% at 18 months (1 year 6 months)
• dose 3 coverage was 83.8% at 18 months (1 year 6 months)
• dose 2 coverage in those aged 6 months has increased by 4.6 percentage points compared with April 2025, prior to the change in schedule, suggesting the change in schedule has had a positive impact on coverage

Note: Historic data has been excluded for the MenB vaccine for April 2020, March 2022, May 2022, October 2022 and between September 2025 and December 2025 after failing validation checks. These periods are indicated by grey bars in the relevant graphs.

Figure 2a. MenB coverage by age group and dose for April 2026

Coverage of MenB dose 2

Measurement of coverage of MenB dose 2 in those aged 6 months gives an indicator of coverage of the primary course and allows us to evaluate the impact of the change in schedule.

Those aged 6 months in April 2026 had been eligible for the second dose of MenB at 3 months (12 weeks), under the new schedule. This means that they had been eligible for 3 months when measured.

The findings for MenB dose 2 in those aged 6 months are that:

• coverage was 89.8%, which was 4.6 percentage points higher than in April 2025 prior to the change in schedule
• coverage by commissioning region differed by 8.1 percentage points, from 85.1% in London to 93.2% in the South West
• coverage by local authority differed by 41.7 percentage points, from 58.3% in Hackney and City of London to 100.0% in Hartlepool

Figure 2b. MenB dose 2 coverage for those aged 6, 12 and 18 months (1 year 6 months) from May 2017 to April 2026

Notes: Grey shaded area represents period where data has been excluded after failing validation checks. Black vertical line represents change in vaccination schedule from being eligible for the second dose at 4 months (16 weeks) to being eligible at 3 months (12 weeks).

Figure 2c. MenB dose 2 coverage for those aged 6 months from May 2017 to April 2026 by historic commissioning region

Note: Grey shaded areas represent period where data has been excluded after failing validation checks.

Figure 2d. MenB dose 2 coverage for those aged 6 months for April 2026 by local authority

Coverage of MenB dose 3

The measurement of coverage of MenB dose 3 at 18 months (1 year 6 months) provides both an indicator of completion of the full course and levels of protection in the population.

Those aged 18 months were eligible for the third booster dose of MenB at 12 months. This means that they had been eligible for 6 months when measured.

The findings for MenB dose 3 in those aged 18 months are that:

• coverage was 83.8%, 0.3 percentage points lower than in April 2025
• coverage by commissioning region differed by 12.2 percentage points, from 76.6% in London to 88.8% in the South West
• coverage by local authority differed by 47.2 percentage points, from 51.0% in Hackney and City of London to 98.2% in North East Lincolnshire
• coverage by IMD 2025 decile differed by 11.6 percentage points, from 76.7% in the most deprived decile to 88.3% in the least deprived decile
• coverage of dose 3 was 10.8 percentage points lower than dose 1 coverage in this cohort

Figure 2e. MenB dose 3 coverage for those aged 18 months (1 year 6 months) from May 2017 to April 2026

Note: Grey shaded area represents period where data has been excluded after failing validation checks.

Figure 2f. MenB dose 3 coverage for those aged 18 months (1 year 6 months) from May 2017 to April 2026 by commissioning region

Note: Grey shaded area represents period where data has been excluded after failing validation checks.

Figure 2g. MenB dose 3 coverage for those aged 18 months (1 year 6 months) for April 2026 by local authority

3.3 The 6-in-1 vaccine

Summary of 6-in-1 coverage

The 6-in-1 vaccine provides protection against diphtheria, tetanus, pertussis, polio, Hib and hepatitis B. Children are eligible for dose 1 at 2 months (8 weeks), dose 2 at 3 months (12 weeks) and dose 3 at 4 months (16 weeks). From January 2026 a fourth booster dose has been added to the schedule at 18 months (1 year 6 months) [see Notes].

The main findings for the 6-in-1 vaccine are that:

• dose 1 coverage was 93.3% at 6 months, 94.5% at 18 months (1 year 6 months), 94.4% at 24 months
• dose 2 coverage was 90.4% at 6 months, 93.0% at 18 months (1 year 6 months), 93.1% at 24 months
• dose 3 coverage was 85.0% at 6 months, 91.5% at 18 months (1 year 6 months), 91.5% at 24 months

Notes: Data is not yet available to assess coverage of the fourth dose of the 6-in-1 vaccine; however, this will be included in future publications. Historic data has been excluded for the 6-in-1 vaccine between May 2022 and March 2023, and for October 2025, after failing validation checks; this period is indicated by grey bars in the relevant graphs.

Figure 3a. 6-in-1 coverage by age group and dose for April 2026

Coverage of 6-in-1 dose 3

Measurement of coverage of 6-in-1 dose 3 in those aged 6 months provides both an indicator of completion of the primary course and levels of protection in the population.

Those aged 6 months were eligible for the third dose of 6-in-1 at 4 months (16 weeks). This means that they had been eligible for 2 months when measured.

The findings for 6-in-1 dose 3 in those aged 6 months are that:

• coverage was 85.0%, which was 0.4 percentage points lower than in April 2025
• coverage by commissioning region differed by 10.4 percentage points, from 79.2% in London to 89.6% in the South West
• coverage by local authority differed by 45.3 percentage points, from 51.8% in Hackney and City of London to 97.1% in West Berkshire
• coverage by IMD 2025 decile differed by 12.8 percentage points, from 78.9% in the most deprived decile to 91.7% in the least deprived decile
• coverage of dose 3 was 8.3 percentage points lower than dose 1 coverage in this cohort

Figure 3b. 6-in-1 dose 3 coverage for those aged 6, 18 and 24 months from February 2019 to April 2026

Notes: Grey shaded area represents period where data has been excluded after failing validation checks. Data for those aged 18 and 24 months only available from September 2025

Figure 3c. 6-in-1 dose 3 coverage for those aged 6 months from February 2019 to April 2026 by historic commissioning region

Note: Grey shaded area represents period where data has been excluded after failing validation checks.

Figure 3d. 6-in-1 dose 3 coverage for those aged 6 months for April 2026 by local authority

3.4 The rotavirus vaccine

Summary of rotavirus coverage

The rotavirus vaccine provides protection against rotavirus which can cause severe diarrhoea and vomiting. Children become eligible for the first dose of rotavirus at 2 months (8 weeks) and the second dose at 3 months (12 weeks).

The main findings for the rotavirus vaccine are that:

• dose 1 coverage was 90.2% at 6 months
• dose 2 coverage was 86.7% at 6 months

Note: Historic data has been excluded for the rotavirus vaccine for September 2023 after failing validation checks; this period is indicated by grey bars in the graphs below.

Coverage of rotavirus dose 2

The measurement of coverage of rotavirus dose 2 at 6 months provides both an indicator of completion of the full course and levels of protection in the population.

Those aged 6 months were eligible for the second dose of rotavirus at 3 months (12 weeks). This means that they had been eligible for 3 months when measured.

The findings for rotavirus dose 2 in those aged 6 months are that:

• coverage was 86.7%, which was 2.0 percentage points lower than in April 2025
• coverage by commissioning region differed by 7.3 percentage points, from 82.2% in London to 89.5% in the South West
• coverage by local authority differed by 43.1 percentage points, from 53.5% in Hackney and City of London to 96.6% in South Tyneside
• coverage by IMD 2025 decile differed by 9.8 percentage points, from 81.9% in the most deprived decile to 91.7% in the least deprived decile
• coverage of dose 2 was 3.5 percentage points lower than dose 1 coverage in this cohort

Figure 4a. Rotavirus dose 2 coverage for those aged 6 months from January 2020 to April 2026

Note: Grey shaded area represents period where data has been excluded after failing validation checks.

Figure 4b. Rotavirus dose 2 coverage for those aged 6 months from January 2020 to April 2026 by historic commissioning region

Note: Grey shaded area represents period where data has been excluded after failing validation checks.

Figure 4c. rotavirus dose 2 coverage for those aged 6 months for April 2026 by local authority

3.5 The dTaP/IPV vaccine

Summary of dTaP/IPV booster coverage

The dTap/IPV booster (pre-school booster) protects against tetanus, diphtheria and polio. The booster dose provides additional protection following completion of the primary course. Children become eligible for the dTaP/IPV booster at around 40 months (3 years 4 months).

The measurement of coverage of the dTaP/IPV booster at 60 months (5 years) provides both an indicator of completion of the full course and levels of protection in the population.

Those aged 60 months (5 years) were eligible for the dTap/IPV booster around 40 months (3 years 4 months). This means that they had been eligible for 20 months when measured.

The findings for dTaP/IPV booster in those aged 60 months (5 years) are that:

• coverage was 83.3% for the booster dose
• coverage by commissioning region differed by 17.3 percentage points, from 71.0% in London to 88.3% in the South West
• coverage by local authority differed by 39.8 percentage points, from 55.9% in Hackney and City of London to 95.7% in County Durham
• coverage by IMD 2025 decile differed by 12.2 percentage points, from 77.2% in the most deprived decile to 89.4% in the least deprived decile

Note: All historic data for the dTaP/IPV booster has been excluded after failing validation checks.

Figure 5a. dTaP/IPV booster coverage for those aged 60 months for April 2026 by local authority

4. Background

Childhood schedule changes

In 2025, the cessation of the Hib/MenC (Menitorix) vaccine, prompted the Joint Committee on Vaccination and Immunisation (JCVI) to review the routine childhood immunisation schedule. This review led to the introduction of a new 18-month appointment offering a fourth dose of 6-in-1 vaccine and bringing forward the second dose of MMR from the original 3 years and 4 months appointment.

From 1 July 2025, the schedule was amended to offer the second dose of the meningococcal B (MenB) vaccine at 12 weeks of age, rather than 16 weeks, to provide earlier protection against invasive meningococcal disease.

In addition, from January 2026, the MMR vaccine was replaced with MMRV, offering children additional protection against varicella, the causative agent for chicken pox.

Eligibility for MMR and MMRV differs depending on when a child was born. This phased rollout ensures that all children receive the required doses of MMR, as well as providing older children the opportunity to receive protection against varicella.

Data sources

Historically, childhood immunisation programmes have been monitored using the Cover of Vaccination Evaluated Rapidly (‘COVER’) collection, which has been published since 1987. COVER is a quarterly collection which reports coverage in those aged 1 year (12 months), 2 years (24 months) and 5 years (60 months). The COVER collection provides a robust long-term view of coverage and remains the definitive source of data on childhood vaccination coverage for England.

The ImmForm Early Childhood Baseline collection was introduced to supplement the COVER collection by measuring coverage in additional age cohorts. Since the collection measures coverage shortly after the vaccine is recommended, it can be used to assess the uptake of vaccinations in a more timely way than COVER. The collection has been adapted over time to allow rapid assessment of coverage following changes to the routine immunisation schedule. This data is available to local teams through the ImmForm website and is used for provisional monitoring of the childhood vaccine programmes.

The main distinction in methodology between these data sources is that COVER data is based on data from Child Health Information Systems (CHIS) whereas ImmForm is based on data extracted by GP IT suppliers, from the GP record. This means that COVER is able to capture all eligible individuals, whereas ImmForm will only include those registered at a GP, meaning some eligible individuals will not be captured. This is likely to disproportionately affect highly transient individuals who are less likely to be registered with a GP.

While these systems provide an established and reliable source of coverage data, the COVID-19 pandemic highlighted the need for real-time individual-level vaccination data. In response to this, the National Immunisation Management system was introduced to provide rapid and granular data on COVID-19 vaccinations. This system has since transitioned into the Immunisation Information System (IIS), which has been expanding to include data on influenza, MMR and RSV.

This report presents data from the ImmForm Early Childhood Baseline collection which provides an earlier snapshot of coverage than is available through COVER. These provisional figures are intended to support those commissioning and administering the programme, where timely data is crucial. For most use cases, COVER should be used, as it provides more accurate figures that include all eligible children. In future, coverage data from IIS will also be available to monitor the childhood immunisation programme, however this data is currently under review.

Aims

The aim of this new report series is to provide provisional coverage estimates to monitor childhood immunisation programs.

This report will assess:

• the impact of changes to the immunisation schedule, including the introduction of the MMRV vaccine and changes to the MenB schedule
• completion of vaccination course in older cohorts
• changes in coverage over time, to identify trends
• variation in coverage by sociodemographic factors

5. Methods

Data completeness

The data presented in this report was collected at the GP practice level and was automatically uploaded via participating GP IT suppliers to ImmForm. Data was then validated and analysed by UKHSA to check data completeness, query any anomalous results and describe epidemiological trends.

A total of 6,085 out of 6,155 (98.9%) GP practices reported data for April 2026. Both main GP IT suppliers (Optum and TPP) provided data.

Definitions

The definitions used in this report are that:

• dose 1 coverage was defined as the proportion of registered children who reached a specified age during the survey month and had received at least one dose of a vaccine at any time before the end of that month
• dose 2 coverage was defined as the proportion of registered children who reached a specified age during the survey month and had received at least one dose of a vaccine at any time before the end of that month
• dose 3 coverage was defined as the proportion of registered children who reached a specified age during the survey month and had received at least one dose of a vaccine at any time before the end of that month

Cohorts

This report presents childhood vaccine coverage data for the following vaccines and age groups:

• MMR and MMRV dose 1 in those aged 15 months (1 year 3 months)
• 6-in-1 doses 1, 2, and 3 in those aged 6, 18 (1 year 6 months) and 24 months
• MenB dose 1 and 2 in those aged 6 months, 12 months and 18 months (1 year 6 months)
• rotavirus dose 1 and 2 in those aged 6 month (25 weeks)
• the dTaP/IPV booster in those aged 60 month (5 years)

Cohorts are defined based on the age they turned during the survey month. The birth cohorts from the current report are shown in the table below.

Birth dates by age cohort for April 2026

Age (months)	Date of birth range
6 months	1 October 2025 to 31 October 2025
12 months	1 April 2025 to 30 April 2025
18 months	1 October 2024 to 31 October 2024
24 months	1 April 2024 to 30 April 2024
60 months	1 April 2021 to 30 April 2021

6. Appendix

Summary of provisional childhood coverage

A summary of coverage for MMRV, MenB, 6-in-1 and rotavirus vaccines, for the dTaP/IPV booster, can be found in table below.

Vaccine coverage (%) for the MMRV, MenB, 6-in-1 and rotavirus vaccines for April 2026, compared with April 2025

Vaccine	Dose	Age	Coverage April 2026 (%)	Coverage April 2025 (%)	Change from previous year
6-in-1	3	6 months	85.0	85.4	-0.4
MMR/MMRV	1	15 months	78.8	78.9	-0.4
MenB	2	6 months	89.8	85.2	4.6
MenB	3	18 months	83.8	84.1	-0.3
Rotavirus	2	6 months	86.7	88.7	-2.0

Abbreviations

MMR: Measles, mumps and rubella vaccine

MMRV: Measles, mumps, rubella and varicella vaccine

MenB: Meningococcal group B vaccine

JCVI: Joint Committee on Vaccination and Immunisation

6-in-1: Hexavalent vaccine

IMD: Index of multiple deprivation